Multitarget stool DNA test compared with fecal occult blood test for colorectal cancer screening

Yang,Cuiping; Wu,Wei; Yang,Yanping; Yang,Xiaojin; Sun,Jing; Zhang,Weiyu; Liu,Kun; Ying,Haifeng; Jiang,Songyao; Yu,Xiaojun; Shi,Yiqing; Zhou,Yufen; Zhu,Shiyan; Xu,Ying; Ding,Yanfei; Xie,Ling; Cai,Boer; Xin,Xiaorong; Chen,Ping; Zhao,Ren; Wu,Yunlin

doi:10.3892/ol.2020.11674

Multitarget stool DNA test compared with fecal occult blood test for colorectal cancer screening

Authors:
- Cuiping Yang
- Wei Wu
- Yanping Yang
- Xiaojin Yang
- Jing Sun
- Weiyu Zhang
- Kun Liu
- Haifeng Ying
- Songyao Jiang
- Xiaojun Yu
- Yiqing Shi
- Yufen Zhou
- Shiyan Zhu
- Ying Xu
- Yanfei Ding
- Ling Xie
- Boer Cai
- Xiaorong Xin
- Ping Chen
- Ren Zhao
- Yunlin Wu
View Affiliations

Affiliations: Department of Gastroenterology, Shanghai Jiao Tong University, School of Medicine, Ruijin Hospital North, Shanghai 201800, P.R. China, Department of Gastroenterology, Shanghai Jiao Tong University, School of Medicine, Ruijin Hospital, Shanghai 200025, P.R. China, Department of Laboratory, Jiujiang Maternity and Child Health Hospital, Jiujiang, Jiangxi 332000, P.R. China, Department of Infection Control, Jiujiang No. 1 People's Hospital, Jiujiang, Jiangxi 332000, P.R. China, Department of Traditional Chinese Medicine, Shanghai Jiao Tong University, School of Medicine, Ruijin Hospital North, Shanghai 200025, P.R. China, Department of General Surgery, Shanghai Jiao Tong University, School of Medicine, Ruijin Hospital North, Shanghai 201800, P.R. China, Department of Traditional Chinese Medicine, Shanghai Jiao Tong University, School of Medicine, Ruijin Hospital North, Shanghai 201800, P.R. China, Department of Nursing Department of Gastroenterology, Shanghai Jiao Tong University, School of Medicine, Ruijin Hospital North, Shanghai 201800, P.R. China
Published online on: May 25, 2020 https://doi.org/10.3892/ol.2020.11674
Pages: 1193-1200
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Patient screening is important for early diagnosis of colorectal cancer (CRC). The present study aimed to compare the multitarget stool DNA (mt‑sDNA) test with the fecal occult blood test (FOBT) for CRC screening. A total of 151 individuals were screened using colonoscopy, mt‑sDNA and FOBT for the detection of CRC and adenoma. The results of the mt‑sDNA test and FOBT were compared with colonoscopy to examine their sensitivity and specificity. Subsequently, the sensitivity and specificity of the mt‑sDNA test were compared with those of FOBT in CRC and large adenoma. Stool samples were collected from patients with CRC (n=50) or large adenoma (n=51), as well as from normal controls (n=50). The mt‑sDNA test outperformed FOBT in detecting CRC with a sensitivity of 90.0% (45/50) vs. 42.0% (21/50), advanced adenoma with a sensitivity of 70.6% (36/51) vs. 19.6% (10/51), stage I‑III CRC with a sensitivity of 91.9% (34/37) vs. 29.7% (11/37), and stage IV CRC with a sensitivity of 84.6% (11/13) vs. 76.9% (10/13). In addition, the mt‑sDNA test exhibited a specificity of 94.0% (47/50) in detecting CRC, which was superior to FOBT with a specificity of 90.0% (45/50). Therefore, the mt‑sDNA test may have higher sensitivity and specificity compared with FOBT in diagnosing both CRC and advanced adenoma.

View Figures

View References

1	Imamura Y, Morikawa T, Liao X, Lochhead P, Kuchiba A, Yamauchi M, Qian ZR, Nishihara R, Meyerhardt JA, Haigis KM, et al: Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin Cancer Res. 18:4753–4763. 2012.PubMed/NCBI
2	Xiao W, Zhao H, Dong W, Li Q, Zhu J, Li G, Zhang S and Ye M: Quantitative detection of methylated NDRG4 gene as a candidate biomarker for diagnosis of colorectal cancer. Oncol Lett. 9:1383–1387. 2015.PubMed/NCBI
3	Luo SL, Hu RY, Gong WW, Wang H, Pan J, Fei FR and Yu M: Survival rate of colorectal cancer patients during 2005–2010 in Zhejiang province, China. Zhonghua Liu Xing Bing Xue Za Zhi. 34:1194–1197. 2013.(In Chinese). PubMed/NCBI
4	Song LL and Li YM: Current noninvasive tests for colorectal cancer screening: An overview of colorectal cancer screening tests. World J Gastrointest Oncol. 8:793–800. 2016.PubMed/NCBI
5	Iannone A, Losurdo G, Pricci M, Girardi B, Massaro A, Principi M, Barone M, Ierardi E and Di Leo A: Stool investigations for colorectal cancer screening: From occult blood test to DNA analysis. J Gastrointest Cancer. 47:143–151. 2016.PubMed/NCBI
6	Ahlquist DA, Harrington JJ, Burgart LJ and Roche PC: Morphometric analysis of the ‘mucocellular layer’ overlying colorectal cancer and normal mucosa: Relevance to exfoliation and stool screening. Hum Pathol. 31:51–57. 2000.PubMed/NCBI
7	Brenner H, Hoffmeister M, Arndt V, Stegmaier C, Altenhofen L and Haug U: Protection from right- and left-sided colorectal neoplasms after colonoscopy: Population-based study. J Natl Cancer Inst. 102:89–95. 2010.PubMed/NCBI
8	Lu H, Huang S, Zhang X, Wang D, Zhang X, Yuan X, Zhang Q and Huang Z: DNA methylation analysis of SFRP2, GATA4/5, NDRG4 and VIM for the detection of colorectal cancer in fecal DNA. Oncol Lett. 8:1751–1756. 2014.PubMed/NCBI
9	Renaud S, Guerrera F, Seitlinger J, Costardi L, Schaeffer M, Romain B, Mossetti C, Claire-Voegeli A, Filosso PL, Legrain M, et al: KRAS exon 2 codon 13 mutation is associated with a better prognosis than codon 12 mutation following lung metastasectomy in colorectal cancer. Oncotarget. 8:2514–2524. 2017.PubMed/NCBI
10	Ross JP, Rand KN and Molloy PL: Hypomethylation of repeated DNA sequences in cancer. Epigenomics. 2:245–269. 2010.PubMed/NCBI
11	Rasmussen SL, Krarup HB, Sunesen KG, Pedersen IS, Madsen PH and Thorlacius-Ussing O: Hypermethylated DNA as a biomarker for colorectal cancer: A systematic review. Colorectal Dis. 18:549–561. 2016.PubMed/NCBI
12	Zou H, Harrington JJ, Shire AM, Rego RL, Wang L, Campbell ME, Oberg AL and Ahlquist DA: Highly methylated genes in colorectal neoplasia: Implications for screening. Cancer Epidemiol Biomarkers Prev. 16:2686–2696. 2007.PubMed/NCBI
13	Hinoue T, Weisenberger DJ, Lange CP, Shen H, Byun HM, Van Den Berg D, Malik S, Pan F, Noushmehr H, van Dijk CM, et al: Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res. 22:271–282. 2012.PubMed/NCBI
14	Mitchell SM, Ross JP, Drew HR, Ho T, Brown GS, Saunders NF, Duesing KR, Buckley MJ, Dunne R, Beetson I, et al: A panel of genes methylated with high frequency in colorectal cancer. BMC Cancer. 14:542014.PubMed/NCBI
15	Melotte V, Lentjes MH, van den Bosch SM, Hellebrekers DM, de Hoon JP, Wouters KA, Daenen KL, Partouns-Hendriks IE, Stessels F, Louwagie J, et al: N-Myc downstream-regulated gene 4 (NDRG4): A candidate tumor suppressor gene and potential biomarker for colorectal cancer. J Natl Cancer Inst. 101:916–927. 2009.PubMed/NCBI
16	Park H, Kim Y, Lim Y, Han I and Oh ES: Syndecan-2 mediates adhesion and proliferation of colon carcinoma cells. J Biol Chem. 277:29730–29736. 2002.PubMed/NCBI
17	Glöckner SC, Dhir M, Yi JM, McGarvey KE, Van Neste L, Louwagie J, Chan TA, Kleeberger W, de Bruïne AP, Smits KM, et al: Methylation of TFPI2 in stool DNA: A potential novel biomarker for the detection of colorectal cancer. Cancer Res. 69:4691–4699. 2009.PubMed/NCBI
18	Oh TJ, Oh HI, Seo YY, Jeong D, Kim C, Kang HW, Han YD, Chung HC, Kim NK and An S: Feasibility of quantifying SDC2 methylation in stool DNA for early detection of colorectal cancer. Clin Epigenetics. 9:1262017.PubMed/NCBI
19	Lao VV and Grady WM: Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol. 8:686–700. 2011.PubMed/NCBI
20	Gerecke C, Scholtka B, Löwenstein Y, Fait I, Gottschalk U, Rogoll D, Melcher R, Kleuser B, et al: Hypermethylation of ITGA4, TFPI2 and VIMENTIN promoters is increased in inflamed colon tissue: Putative risk markers for colitis-associated cancer. J Cancer Res Clin Oncol. 141:2097–2107. 2015.PubMed/NCBI
21	Kadiyska T and Nossikoff A: Stool DNA methylation assays in colorectal cancer screening. World J Gastroenterol. 21:10057–10061. 2015.PubMed/NCBI
22	Zou H, Taylor WR, Harrington JJ, Hussain FT, Cao X, Loprinzi CL, Levine TR, Rex DK, Ahnen D, Knigge KL, et al: High detection rates of colorectal neoplasia by stool DNA testing with a novel digital melt curve assay. Gastroenterology. 136:459–470. 2009.PubMed/NCBI
23	Ahlquist DA, Zou H, Domanico M, Mahoney DW, Yab TC, Taylor WR, Butz ML, Thibodeau SN, Rabeneck L, Paszat LF, et al: Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology. 142:248–256. 2012.PubMed/NCBI
24	Green MR and Sambrook J: Hot start polymerase chain reaction (PCR). Cold Spring Harb Protoc. 2018:2018.
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI
26	Jiang X, Harrington JJ, Mahoney DW, Oberg AL, Devens ME, Simonson J, Ahlquist DA and Zou H: T1102 detection of colorectal neoplasia by stool DNA testing: High discrimination with multi-marker quantitation. Gastroenterology. 134 (Suppl 1):A–484. 2008.
27	Huang Z, Li L and Wang J: Hypermethylation of SFRP2 as a potential marker for stool-based detection of colorectal cancer and precancerous lesions. Dig Dis Sci. 52:2287–2291. 2007.PubMed/NCBI
28	Baek YH, Chang E, Kim YJ, Kim BK, Sohn JH and Park DI: Stool methylation-specific polymerase chain reaction assay for the detection of colorectal neoplasia in Korean patients. Dis Colon Rectum. 52:1452–1459. 2009.PubMed/NCBI
29	Bleeker WA, Hayes VM, Karrenbeld A, Hofstra RM, Hermans J, Buys CC and Plukker JT: Impact of KRAS and TP53 mutations on survival in patients with left- and right-sided Dukes' C colon cancer. Am J Gastroenterol. 95:2953–2957. 2000.PubMed/NCBI
30	Zauber AG: The impact of screening on colorectal cancer mortality and incidence: Has it really made a difference? Dig Dis Sci. 60:681–691. 2015.PubMed/NCBI
31	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI
32	Yang D, Hillman SL, Harris AM, Sinicrope PS, Devens ME and Ahlquist DA: Patient perceptions of stool DNA testing for pan-digestive cancer screening: A survey questionnaire. World J Gastroenterol. 20:4972–4979. 2014.PubMed/NCBI